AI In Precision Medicine: From Predictive Insight To Operational Confidence In Complex Clinical Trials

By David Berry, manager, data sciences andLee Coram, head of Digital Success and Collaboration Office

Precision medicine is increasing the complexity of clinical trial planning by requiring sponsors to integrate information across biomarker-defined populations, diagnostics, laboratories, sites, patients, and operational teams. Managing this breadth of information requires strong data quality, interoperability, governance, security, and privacy practices. These foundations are becoming particularly important as biopharmaceutical organizations adopt artificial intelligence (AI), large language models (LLMs), and agentic systems for clinical operations.

The most significant opportunity for AI may be moving trial management from a reactive to a predictive model. By continuously analyzing enrollment trends, protocol deviations, query volumes, staffing patterns, historical site performance, and other operational signals, AI can identify emerging risks before they affect study timelines. This can help teams prioritize interventions and allocate resources more effectively, particularly in precision medicine studies involving smaller patient populations and complex eligibility criteria.

However, AI cannot compensate for fragmented or inconsistent data. Organizations should establish standardized data structures, scalable storage, robust governance, and security controls before deploying advanced AI capabilities. Conventional statistical approaches may remain appropriate when datasets are limited or relatively straightforward. As operational datasets grow, AI can identify complex relationships across therapeutic areas, geography, site performance, enrollment behavior, and study design, generating forward-looking insights while leaving interpretation, accountability, and final decisions with clinical and operational experts.